SANUWAVE Health, Inc.
NASDAQ:SNWVMedical - Devices
+$0.18 today
- Market cap
- $51.01M
- Beta
- 1.34
- P/E (TTM)
- 5.0
- EPS (TTM)
- $1.87
Volume 0.04M
Average 0.11M
SNWV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SANUWAVE Health, Inc.NASDAQ: SNWV
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$581K, compared with -$3.55M a year earlier. Trailing-twelve-month EBITDA was $22.67M. Over 3 fiscal years it compounded at +59.4% a year.
Context
- EBITDA amounted to 44.1% of revenue in FY2025, down 6.7 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$12.62M (-165.0%) for the fiscal year ending Dec 2026, a slowdown from the +217.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$581K-107.6% QoQ
- Last fiscal yearDec 2025
- $19.43M+217.3% YoY
- LTMMar 2026
- $22.67M+217.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +83.6% | -187.6% | -271.2 pp |
| 1 year | +217.3% | -165.0% | -382.3 pp |
| 3-year CAGR | +59.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 19.43M USD
- Year-over-year change
- +217.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.43M | +217.3% |
| FY2024 | 2024-12-31 | (16.56M) | -81.0% |
| FY2023 | 2023-12-31 | (9.15M) | -290.9% |
| FY2022 | 2022-12-31 | 4.79M | +125.4% |
| FY2021 | 2021-12-31 | (18.9M) | — |
EBITDA vs competitors
How SNWV compares with its peers on the latest reported figures
- SNWV's LTM Mar 2026 EBITDA of $22.67M is the highest of the 11 companies compared; the peer median is -$60.6M.
- Its year-over-year change of +217.1% is the highest of 11, against a peer median of +6.1%.
- EBITDA amounts to 51.1% of revenue for SNWV, versus a peer median of 58.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.67M | +217.1% | +59.4% | 51.1% | |
| LTM Mar 2026 | -$5.23M | +26.2% | — | 1.5% | |
| LTM Mar 2026 | -$26.57M | +5.3% | — | 46.0% | |
| LTM Mar 2026 | -$31.68M | +27.7% | — | 39.8% | |
| LTM Dec 2025 | -$49M | -11.0% | — | 376.3% | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$62.35M | +22.0% | — | 53.0% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$80.8M | -25.3% | — | 198.5% | |
| LTM Mar 2026 | -$84.67M | -104.0% | — | 58.4% | |
| LTM Mar 2026 | -$135.55M | -1012.4% | — | 1413.6% | |
| Peer median (excluding SNWV) | -$60.6M | +6.1% | — | 58.4% | |
Competitors are the stored peer set for SNWV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.01M | 16.74M | 20.4M | 32.63M | 44.05M |
| Cost of Revenue | 4.99M | 4.33M | 6.04M | 8.08M | 10.08M |
| Gross Profit | 8.02M | 12.41M | 14.36M | 24.55M | 33.97M |
| Gross Margin | 61.7% | 74.1% | 70.4% | 75.2% | 77.1% |
| Research & Development | 1.1M | 567K | 579K | 673K | 1.35M |
| Selling, General & Admin | 20.28M | 20.03M | 13.57M | 17.67M | 26.79M |
| Operating Expenses | 22.17M | 21.36M | 14.9M | 19.13M | 29.02M |
| Depreciation & Amortization | 1.24M | 952K | 1.03M | 1.15M | 1.28M |
| EBITDA | (18.9M) | 4.79M | (9.15M) | (16.56M) | 19.43M |
| EBITDA Margin | -145.3% | 28.6% | -44.9% | -50.8% | 44.1% |
| Operating Income | (14.14M) | (8.95M) | (540K) | 5.42M | 4.95M |
| Operating Margin | -108.7% | -53.5% | -2.6% | 16.6% | 11.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 7.1M | 14.13M | 15.62M | 13.64M | 6.25M |
| Other Income / Expenses | (13.09M) | (1.34M) | (25.26M) | (36.76M) | 6.95M |
| Income Before Tax | (27.23M) | (10.29M) | (25.8M) | (31.35M) | 11.9M |
| Pre-Tax Margin | -209.3% | -61.5% | -126.5% | -96.1% | 27.0% |
| Income Tax Expense | 28K | 2K | 4K | 27K | 86K |
| Net Income | (27.26M) | (10.29M) | (25.81M) | (31.37M) | 11.81M |
| Net Margin | -209.5% | -61.5% | -126.5% | -96.1% | 26.8% |
| EPS (Basic) | (19.72) | (7.02) | (12.19) | (7.03) | 1.38 |
| EPS (Diluted) | (19.72) | (7.02) | (12.19) | (7.03) | 0.41 |
| Weighted Avg Shares | 1.38M | 1.47M | 2.12M | 4.46M | 8.56M |
| Weighted Avg Shares (Diluted) | 1.38M | 1.47M | 2.12M | 4.46M | 9.08M |
SANUWAVE Health, Inc.
NASDAQ:SNWV
Intrinsic Alpha fair value
Locked
Current Price
$5.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.